Test-retest reproducibility of [11C]-L-deprenyl-D2 binding to MAO-B in the human brain. 2017

Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden. ryosuke.arakawa@ki.se.

BACKGROUND [11C]-L-deprenyl-D2 is a positron emission tomography (PET) radioligand for measurement of the monoamine oxidase B (MAO-B) activity in vivo brain. The estimation of the test-retest reproducibility is important for accurate interpretation of PET studies. RESULTS We performed two [11C]-L-deprenyl-D2 scans for six healthy subjects and evaluated the test-retest variability of this radioligand. MAO-B binding was quantified by two tissue compartment model (2TCM) with three rate constants (K 1, k 2, k 3) using metabolite-corrected plasma radioactivity. The λk 3 defined as (K 1/k 2) × k 3 was also calculated. The correlation between MAO-B binding and age, and the effect of partial volume effect correction (PVEc) for the reproducibility were also estimated. %difference of k 3 was 2.6% (medial frontal cortex) to 10.3% (hippocampus), and that of λk 3 was 5.0% (thalamus) to 9.2% (cerebellum). Mean %difference of all regions were 5.3 and 7.0% in k 3 and λk 3, respectively. All regions showed below 10% variabilities except the hippocampus in k 3 (10.3%). Intraclass correlation coefficient (ICC) of k 3 was 0.78 (hippocampus) to 0.98 (medial frontal cortex), and that of λk 3 was 0.78 (hippocampus) to 0.95 (thalamus). Mean ICC were 0.94 and 0.89 in k 3 and λk 3, respectively. The highest positive correlation with age was observed in the hippocampus, as r = 0.75 in k 3 and 0.76 in λk 3. After PVEc, mean %difference were 5.6 and 7.2% in k 3 and λk 3, respectively. Mean ICC were 0.92 and 0.90 for k 3 and λk 3, respectively. These values were almost the same as those before PVEc. CONCLUSIONS The present results indicate that k 3 and λk 3 of [11C]-L-deprenyl-D2 are reliable parameters for test-retest reproducibility with healthy subjects both before and after PVEc. The studies with patients of larger sample size are required for further clinical applications.

UI MeSH Term Description Entries

Related Publications

Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
January 2000, Nuclear medicine and biology,
Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
April 2013, European journal of nuclear medicine and molecular imaging,
Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
May 2009, Clinical pharmacology and therapeutics,
Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
January 1990, Journal of neural transmission. Supplementum,
Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
October 1994, Synapse (New York, N.Y.),
Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
January 2011, Neurochemistry international,
Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
January 1987, Advances in neurology,
Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
February 2014, European journal of nuclear medicine and molecular imaging,
Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
January 1995, Brain research bulletin,
Ryosuke Arakawa, and Per Stenkrona, and Akihiro Takano, and Sangram Nag, and Rafael S Maior, and Christer Halldin
January 1989, Journal of neural transmission,
Copied contents to your clipboard!